Gilead Sciences lenacapavir shows potential in transforming HIV clinical care

New data presented by Gilead Sciences, Inc. has highlighted the efficacy, safety, and patient tolerability of Sunlenca (lenacapavir), the first long-acting injectable HIV treatment administered ... Read More